Cipla’s Novel Patent Suit Could Set Generics Precedent In India
This article was originally published in PharmAsia News
Executive Summary
A patent fight between India's Cipla generics maker and Roche could have major consequences for generics makers. The case being considered by the Delhi high court involves Cipla launching a copy of Roche's Tarceva (erlotinib) even though the Swiss company had an Indian patent for the drug. Cipla reportedly intends to press a case the patent should not have been granted in the first place. Roche challenges Cipla's decision to launch a generic before getting a court ruling on the Roche patent, a novel approach in India. (Click here for more